Ischemic Stroke clinical trials at UCSF
4 in progress, 3 open to eligible people
Sleep for Stroke Management and Recovery Trial
open to eligible people ages 18 years and up
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
San Francisco 5391959, California 5332921 and other locations
Stroke Recovery Initiative - Registry for Stroke Research Studies
open to eligible people ages 18 years and up
The Stroke Recovery Initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.
San Francisco 5391959, California 5332921
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
open to eligible people ages 18 years and up
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
San Francisco 5391959, California 5332921 and other locations
Focal Cerebral Arteriopathy Steroid Trial
Sorry, accepting new patients by invitation only
This comparative effectiveness trial (CET) in children with suspected focal cerebral arteriopathy (FCA) presenting with arterial ischemic stroke (AIS) or transient ischemic attack (TIA) will compare the use of early corticosteroid treatment (Arm A) versus delayed/no corticosteroid treatment (Arm B). Delayed corticosteroid treatment is given only for those demonstrating disease progression and is initiated as soon as the progression is detected (at any time after randomization). All participants will also receive standard of care therapy (aspirin and supportive care). Sites will randomize participants 1:1 to Arm A or B. Participants will be enrolled and randomized as soon as possible after their stroke/TIA up until 96 hours following the initial stroke/TIA event.
San Francisco 5391959, California 5332921
Our lead scientists for Ischemic Stroke research studies include Cathra Halabi, MD Anthony S. Kim, MD, MAS Wade Smith, MD, PhD Heather J Fullerton, MD, MAS.
Last updated: